LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akciju saraksts・MannKind Corp

MannKind Corp

Slēgts

SektorsVeselības aprūpe

3.36 1.82

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.3

Max

3.45

Galvenie mērījumi
By Trading Economics
Ienākumi	-671K -17M
Pārdošana	-22M 90M
P/E Sektora vidējais	140.5 49.701
EPS	-0.02
Peļņas marža	-18.431
Darbinieki	591
EBITDA	5.9M 3.4M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+127.79% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	56M 924M
Iepriekšējā atvēršanas cena	1.54
Iepriekšējā slēgšanas cena	3.36

Ziņu noskaņojums

By Acuity

60%

40%

291 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

4.079 / 4.323 Atbalsts un pretestība

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. maijs 16:33 UTC

Peļņas

Galvenie tirgus virzītāji

Webull Shares Slide on 1Q Loss, Soaring Costs

2026. g. 22. maijs 21:10 UTC

Peļņas

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 19:47 UTC

Peļņas

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026. g. 22. maijs 19:17 UTC

Tirgus saruna

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026. g. 22. maijs 19:10 UTC

Tirgus saruna

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026. g. 22. maijs 18:38 UTC

Tirgus saruna

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026. g. 22. maijs 18:35 UTC

Iegādes, apvienošanās, pārņemšana

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026. g. 22. maijs 18:09 UTC

Tirgus saruna

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026. g. 22. maijs 17:58 UTC

Tirgus saruna

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

2026. g. 22. maijs 17:03 UTC

Tirgus saruna

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

2026. g. 22. maijs 16:54 UTC

Tirgus saruna

Crypto Spot Volumes Fall 14% in April -- Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 16:16 UTC

Tirgus saruna

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

2026. g. 22. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 22. maijs 15:55 UTC

Tirgus saruna

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

2026. g. 22. maijs 15:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 22. maijs 15:42 UTC

Tirgus saruna

Oil Continues as Leading Indicator for All Markets -- Market Talk

2026. g. 22. maijs 15:35 UTC

Tirgus saruna

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

127.79% augšup

Prognoze 12 mēnešiem

Vidējais 7.54 USD 127.79%

Augstākais 10 USD

Zemākais 4.75 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MannKind Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.079 / 4.323Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

291 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.